Good morning,
A warm welcome to new readers, and a big thank you to those who join us each week.
In today's free edition:
π¨π Basel: Roche breaks ground on CHF 500 million R&D building
π¨π Basel: Novartis invests $80 million in RNA production expansion
πͺπΈ Barcelona: Sanofi leases 15,000 sq m Global Innovation Campus
π For paying members only:
π«π· Paris: Atland acquires Sienna, builds β¬10bn pan-European platform
π¬π§ London: Nuveen to acquire Schroders in Β£9.9 billion deal
π¬π§ Blue Owl eyes Β£1.3 billion UK hospital portfolio
π¬π§ Narayana Health to acquire 12 UK hospitals
π©πͺ Landshut: HAL acquires fully let medical centre
π¬π§ Billingham: Fujifilm completes Β£400 million biomanufacturing expansion
π©πͺ Munich: Neues Hauner hospital reaches topping-out milestone
π©πͺ Kiel: HOCHTIEF wins β¬230 million research PPP contract
π΅π± Kajetany: Adamed opens 3,500 sq m R&D headquarters
π΅π± BΕonie: Arvato expands pharma logistics footprint
π¨πΏ Prague: Dr. Max renews 6,300 sq m lease
π¬π§ Bruntwood SciTech invests Β£165 million in science schemes
Subscribe here to unlock.
Enjoy today's newsletter,
β Stephen Ryan (connect with me on LinkedIn)
Basel: Roche breaks ground on CHF 500 million R&D building
In Q4 2025, Roche broke ground on Building 12 at its Basel headquarters, marking a significant milestone in the strategic development of the campus.
Designed by Herzog & de Meuron, the 72-metre, 15-storey facility spans 32,200 sq m and will accommodate approximately 450 researchers across flexible R&D space. Completion is scheduled for Q4 2029.
The CHF 500 million investment consolidates previously dispersed research functions into a single state-of-the-art building, promoting collaboration and research efficiency.
Since 2015, Roche has invested approximately CHF 8 billion across its Swiss sites.
Basel: Novartis invests $80 million in RNA production expansion
In Q4 2025, Novartis announced it will invest $80 million in production facilities at its Schweizerhalle site near Basel.
The investment will expand manufacturing capacity for siRNA and RNA medicines, creating around 80 new jobs by 2028.
The capital expenditure forms part of a restructuring of Novartis's Swiss manufacturing footprint affecting both the Schweizerhalle and Stein sites.
The investment in innovative RNA production technology represents a shift towards higher-technology pharmaceutical manufacturing at the Basel-area facility.
π Need deeper insight into life sciences real estate?
In addition to this newsletter, we deliver bespoke research and strategic analysis for investors and developers β from acquisition support to market mapping and custom reporting.
Get in touch to discuss your next project.
Barcelona: Sanofi leases 15,000 sq m Global Innovation Campus
Sanofi has signed a long-term lease for around 15,000 sq m across two internally connected buildings on Carrer Pamplona in Barcelona's 22@ innovation district, creating Campus Sanofi Barcelona.
The campus will consolidate Sanofi's global hub and local operations into a single location, accommodating more than 1,000 employees in data science, artificial intelligence and biostatistics when it becomes operational in the second half of 2027.
The buildings are owned by REInvest Asset Management and KKH Property Investors.
Gensler designed the interiors. CBRE EspaΓ±a advised Sanofi on the transaction.
π As a free member, youβre only seeing 3 of 15 deals this week.
Subscribers see them all so why not take a 14-day trial?
